Current Hypertension Reports[JOURNAL]
Sun
200 papers
Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.
Colombari E, Pedrino GR, Katayama PL … +4 more , Zoccal DB, Mendonça MM, Colombari DSA, Xavier CH
Curr Hypertens Rep · 2026 Jun · PMID 42377664 · Full text
PURPOSE OF REVIEW: Tissue perfusion is tightly regulated by central neural circuits that integrate autonomic and sensory inputs to match blood flow to tissue metabolic demand. This review synthesizes current knowledge on...
PURPOSE OF REVIEW: Tissue perfusion is tightly regulated by central neural circuits that integrate autonomic and sensory inputs to match blood flow to tissue metabolic demand. This review synthesizes current knowledge on the central mechanisms governing tissue perfusion in both physiological and pathological states, with emphasis on the organization of brain networks involved in cardiovascular control. RECENT FINDINGS: Recent advances reveal that tissue perfusion is modulated not only by classical reflex pathways, but also by humoral, metabolic, immune, and neuromodulatory systems. Key brain regions, particularly within the brainstem, coordinate sympathetic and parasympathetic outflows through complex and state-dependent interactions that dynamically regulate vasomotion and cardiac function. Emerging evidence also demonstrates that maladaptive remodeling of these central networks contributes to vascular dysfunction in disorders such as hypertension and heart failure, promoting tissue hypoxia and end-organ damage. Central neural mechanisms play a pivotal role in the regulation of tissue perfusion under both healthy and diseased conditions. A comprehensive understanding of the neural circuits and signaling pathways involved in perfusion control may support the development of targeted therapeutic strategies aimed at restoring vascular homeostasis and improving outcomes in cardiocirculatory and neurovascular diseases.
Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies D, Dreher L, Wenzel UO
Curr Hypertens Rep · 2026 Jun · PMID 42366305 · Full text
Abstract loading — click title to view on PubMed.
Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.
O'Keeffe J, Kingshill C, Tompson J … +2 more , South AM, Baker-Smith CM
Curr Hypertens Rep · 2026 Jun · PMID 42337185 · Full text
PURPOSE OF REVIEW: The purpose of this review is to describe the intersection between pediatric hypertension and advancing stages of cardiovascular, kidney metabolic syndrome in children and adolescents. RECENT FINDINGS:...
PURPOSE OF REVIEW: The purpose of this review is to describe the intersection between pediatric hypertension and advancing stages of cardiovascular, kidney metabolic syndrome in children and adolescents. RECENT FINDINGS: Cardiovascular-kidney-metabolic syndrome is highly prevalent in the pediatric population. The onset of CKM in childhood is influenced by the presence of antenatal risk factors such as maternal hypertensive disorders of pregnancy. Advancing stages of CKM in children and adolescents are strongly influenced by food insecurity and social determinants of health that impact the risk for childhood obesity. Activation of the renin-angiotensin-aldosterone system is a key mediator in the relationship between antenatal risk, early life course exposure and hypertension in children and adolescents. Effective strategies for slowing the rate of advancement of CKM staging in children and adolescents require attention to early course factors that influence the development of hypertension and obesity. Likewise, management strategies and therapeutic interventions that address these factors are critical to mitigating CKM stage advancement. Although hypertension is a component of the CKM framework, the presence of hypertension in children and adolescents drives higher CKM staging. Together, hypertension and higher CKM staging are associated with increased atherosclerotic cardiovascular disease risk. Social factors, including access to healthy foods and attention to early life course nutrition are critical strategies to improving CKM and hypertension related outcomes in children and adolescents.
Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?
Dunn JM, Sammons SR, Umanath K … +1 more , Dwyer JP
Curr Hypertens Rep · 2026 Jun · PMID 42283874 · Publisher ↗
PURPOSE OF REVIEW: To evaluate the emerging role of aldosterone synthase inhibitors (ASIs) in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors for the management of uncontrolled hypertension in patients...
PURPOSE OF REVIEW: To evaluate the emerging role of aldosterone synthase inhibitors (ASIs) in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors for the management of uncontrolled hypertension in patients with chronic kidney disease (CKD), and to assess their potential cardiorenal benefits. RECENT FINDINGS: SGLT2 inhibitors confer modest blood pressure reduction alongside cardiorenal protection across diverse CKD populations. ASIs such as baxdrostat and lorundrostat demonstrate clinically meaningful reductions in systolic blood pressure, with early evidence suggesting favorable effects on albuminuria. Recent trials in CKD populations demonstrate improved blood pressure control and reductions in proteinuria, while combination therapy suggests mitigation of hyperkalemia risk through SGLT2 inhibitor-induced kaliuresis. Ongoing large-scale trials are evaluating long-term renal and cardiovascular outcomes of this combination strategy. The combination of ASIs and SGLT2 inhibitors represents a mechanistically complementary approach to targeting RAAS dysregulation, volume status, and metabolic pathways. This strategy has the potential to redefine treatment paradigms for CKD-associated uncontrolled hypertension, pending evaluation of long-term outcome benefits.
Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.
Shankar B, Ben-Shlomo A, Cheng S … +1 more , Ebinger JE
Curr Hypertens Rep · 2026 Jun · PMID 42228215 · Publisher ↗
PURPOSE OF REVIEW: Resistant hypertension (RH) affects more than a tenth of adults and yet remains relatively underrecognized and undertreated. The electronic health record (EHR) now stands as a critical tool for overcom...
PURPOSE OF REVIEW: Resistant hypertension (RH) affects more than a tenth of adults and yet remains relatively underrecognized and undertreated. The electronic health record (EHR) now stands as a critical tool for overcoming barriers to the diagnosis and treatment of RH, specifically with respect to aiding in detection, excluding alternate diagnoses, and guiding clinical decision making. We review how the EHR has clarified the population level prevalence of RH and its impact on both quality of life and longevity. RECENT FINDINGS: We examine how the EHR can be leveraged to identify relevant specific causes of elevated blood pressure such as medication non-adherence, clinical inertia, White Coat Effect, and hyperaldosteronism, among others. Additionally, we highlight the promises and potential pitfalls that warrant consideration when implementing novel EHR interventions to address clinical challenges such as RH. In particular, we discuss the importance of balancing augmented data availability with the need for streamlined data flow to clinicians, so that enhanced workflows can both maximize efficiency and improve quality of care. As the EHR continues to transform the practice of care delivery, RH represents a uniquely well-suited area for improving clinical identification and management in ways that could not be otherwise readily achieved in practice.
Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?
Kylies D, Dreher L, Wenzel UO
Curr Hypertens Rep · 2026 May · PMID 42091772 · Full text
PURPOSE OF REVIEW: This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. It examines their effects on bl...
PURPOSE OF REVIEW: This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. It examines their effects on blood pressure reduction, underlying mechanisms, clinical benefits, and implications for future guidelines. RECENT FINDINGS: Recent large-scale trials demonstrate that incretin-based therapies such as semaglutide and tirzepatide significantly reduce body weight, blood pressure, and cardiovascular outcomes. Mediation analyses indicate that weight loss explains a substantial proportion of blood pressure reduction, while direct effects on vascular function, renal sodium handling, and neurohumoral pathways also contribute. These effects are consistent across diverse populations, including individuals without overt hypertension. Incretin-based therapies represent a promising approach in hypertension management, combining metabolic and cardiovascular benefits. Despite the lack of trials with blood pressure as a primary endpoint, current evidence supports their use in selected high-risk populations and suggests an emerging role in future guideline recommendations.
A Review of Clinical Trial and Meta-Analyses of BP Treatment Strategies for Patients with Orthostatic Hypotension: Blood Pressure Management in Patients with Hypertension and Orthostatic Hypotension.
Rajesh S, Lee GR, Gao KJ … +2 more , Verma A, Juraschek SP
Curr Hypertens Rep · 2026 Apr · PMID 42033492 · Full text
PURPOSE OF REVIEW: To review clinical trial and meta-analysis data on the effects of blood pressure (BP) pharmacologic treatment for hypertension on orthostatic hypotension (OH) to identify BP goals for patients with the...
PURPOSE OF REVIEW: To review clinical trial and meta-analysis data on the effects of blood pressure (BP) pharmacologic treatment for hypertension on orthostatic hypotension (OH) to identify BP goals for patients with these concomitant conditions. FINDINGS: Hypertension and OH are commonly found together. The autonomic reflex that prevents hypotension upon standing also prevents hypertension when supine. OH, a fixed difference in systolic BP (≥ 20 mmHg) or diastolic BP (≥ 10 mmHg) between supine (or seated) and standing positions, can thus be associated with adverse outcomes related to low BP (e.g., syncopal events and falls) or high BP (e.g., coronary heart disease and stroke). While all OH stems from some degree of autonomic dysfunction, the type and extent of deficit has implications on the severity and reproducibility of the OH. Treatment strategies, moreover, differ based on predominant risks as well as OH etiology, specifically: neurologic, acute, pharmacologic, or hypertensive (cardiovascular). Hypertensive (cardiovascular) OH has been viewed traditionally through the lens of hypotensive event prevention, but emerging evidence suggests that more intensive therapy may reduce OH and prevent CVD disease with minimal effects on hypotensive events. Careful medication selection, however, is essential to reduce supine or seated hypertension, improve orthostatic BP regulation, and prevent hypotensive complications of treatment in these complex patients. Mounting evidence does not consider OH a deterrent for hypertension management; however, careful phenotyping of OH etiology and patient risks are essential for more precise patient care.
Environmental Determinants of Sleep and Hypertension: A Critical Review of Evidence and Mechanisms.
Vashist K, Shipman-Lacewell J, Peterson S … +2 more , Phillips K, Johnson DA
Curr Hypertens Rep · 2026 Apr · PMID 41996027 · Publisher ↗
PURPOSE OF REVIEW: Examine current evidence on the impact of environmental exposures including noise, light at night, air pollution, temperature, metals, greenspace, and neighborhood on sleep and hypertension. RECENT FI...
PURPOSE OF REVIEW: Examine current evidence on the impact of environmental exposures including noise, light at night, air pollution, temperature, metals, greenspace, and neighborhood on sleep and hypertension. RECENT FINDINGS: Light exposure during sleep, air pollution (especially ozone), higher temperature, and neighborhood disadvantage were consistently associated with poor sleep; associations for noise (children), metals (adults), greenspace, and walkability were mixed. For hypertension, air pollution, increased ambient heat, and neighborhood disadvantage showed consistent associations whereas findings for noise, light, and greenspace had mixed findings. Neighborhood reinvestment, social cohesion, and safer environment was associated with healthier sleep and normal blood pressure. Minoritized and low-socioeconomic status populations face greater environmental exposures and had higher risk of poor sleep and hypertension. Pregnancy represents a window of vulnerability to the effects of air pollution, heat, humidity, and metals on hypertension. Future research should employ personal sensors for better exposure assessments and longitudinal designs to determine causal pathways.
Does Resistance Training Provide Benefits that Are Comparable to Aerobic Exercise in Hypertension?
Tanaka H, Ferrari R
Curr Hypertens Rep · 2026 Apr · PMID 41961158 · Full text
PURPOSE OF REVIEW: Historically, blood pressure (BP) guidelines emphasized the implementation of aerobic exercise. However, more recent guidelines started highlighting the benefits of resistance exercise. The primary aim...
PURPOSE OF REVIEW: Historically, blood pressure (BP) guidelines emphasized the implementation of aerobic exercise. However, more recent guidelines started highlighting the benefits of resistance exercise. The primary aim of this brief review is to determine if resistance training offers comparable benefits to aerobic exercise on BP in individuals with hypertension. RECENT FINDINGS: Aerobic exercise training consistently produces the greatest effect, lowering systolic/diastolic BP by ~ 7/5 mmHg in individuals with hypertension. Dynamic resistance training elicits more modest reductions (~ 2/2 mmHg), whereas isometric resistance training, though evaluated in fewer and smaller studies, has shown clinically meaningful reductions of ~ 5/5 mmHg. However, the impacts of resistance exercise training on ambulatory BP remain non-significant and marginal. Strategies to reduce BP should prioritize aerobic exercise rather than resistance training, especially when the primary goal is BP management.
Attributable Risk of Hypertension for Cardiovascular Disease.
Mace HP, Clark D
Curr Hypertens Rep · 2026 Mar · PMID 41886200 · Full text
PURPOSE OF REVIEW: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, and hypertension is a modifiable risk factor with the strongest association for developing heart disease. This review eval...
PURPOSE OF REVIEW: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, and hypertension is a modifiable risk factor with the strongest association for developing heart disease. This review evaluates the attributable risk of hypertension for CVD at the population level and examines how this risk varies by demographic, geographic, and socioeconomic factors. Understanding the extent to which hypertension contributes to CVD can help inform targeted prevention and intervention treatment strategies. RECENT FINDINGS: Recent studies have examined the attributable risk of hypertension for CVD across different populations. Hypertension had the highest population attributable risk (PAR) and population attributable fraction (PAF) values for overall CVD, stroke, heart failure, and coronary heart disease, especially among Black adults, younger individuals, and residents of low- and middle-income countries. Although hypertension prevalence has increased over time, some high-income countries have observed a decline in its attributable risk for CVD. This decline is likely due to improved blood pressure management and public health interventions. In the US, recent data shows blood pressure control among adults remains low. Population-level interventions such as sodium restrictions in the food supply, standardized treatment protocols to improve blood pressure control, and improved healthcare access have been shown to mitigate the burden of hypertension. Despite advancements in awareness and treatment, hypertension continues to be a major driver of the global CVD burden. The meaningful attributable risk for CVD highlights the need for improved public health protocols. Interventions that combine clinical management with population-level prevention strategies offer the greatest potential for reducing disparities and improving cardiovascular outcomes.
Low-Dose Aspirin Recommendations for Preeclampsia Risk Reduction: A Systematic Review Focused on Black Patients : Current Hypertension Reports.
Zha Y, Mikhailov NJ, Brucia KH … +3 more , Gao J, Alleman E, Ferdinand KC
Curr Hypertens Rep · 2026 Mar · PMID 41857233 · Full text
PURPOSE: Daily low-dose aspirin (LDA) is guideline recommended for preeclampsia prevention, but racial/ethnic disparities persist in its implementation. This systematic review examines disparities in LDA prescription, re...
PURPOSE: Daily low-dose aspirin (LDA) is guideline recommended for preeclampsia prevention, but racial/ethnic disparities persist in its implementation. This systematic review examines disparities in LDA prescription, recommendation and adherence for preeclampsia risk reduction among Black patients compared with other racial/ethnic groups in the United States. RECENT FINDINGS: Overall, LDA prescription/recommendation rates range widely across included studies, from 10.7% to 95% among eligible patients. Black patients are shown to have a similar prescription/recommendation rate compared to White patients. Adherence rates average around 70%, with Black patients showing lower adherence rates despite similar prescription/recommendation rates than White patients. Barriers identified included inconsistent counseling, limited access to prenatal care, and distrust of the healthcare system. While prescribing practices for LDA appear increasingly equitable across racial/ethnic groups, significant disparities remain in adherence among Black women, potentially contributing to worse maternal outcomes. Reducing these gaps requires culturally tailored patient education, improved physician–patient communication, and systems-level interventions that integrate adherence monitoring into prenatal care.
Updates in the 2025 AHA/ACC Hypertension Guideline.
Brown C, Clark D, Jones DW
Curr Hypertens Rep · 2026 Mar · PMID 41843050 · Full text
PURPOSE OF REVIEW: Hypertension remains a leading cause of cardiovascular morbidity and mortality in the United States. The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Man...
PURPOSE OF REVIEW: Hypertension remains a leading cause of cardiovascular morbidity and mortality in the United States. The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of High Blood Pressure in Adults provides the first major update since 2017. It reveals new evidence in the diagnosis, risk assessment, and treatment of hypertension. This review summarizes key updates, contrasts them with prior recommendations, and discusses implications for clinical practice. RECENT FINDINGS: The 2025 AHA/ACC Hypertension Guideline introduces several major updates that reshape risk assessment, diagnosis, and treatment strategy. Adoption of the PREVENT risk calculator replaces the pooled cohort equations, improving cardiovascular risk estimation by incorporating renal function, statin use, and social drivers of health. Screening for primary aldosteronism is expanded to all patients with stage 2 or resistant hypertension, addressing underdiagnosis of this secondary cause. Renal denervation is introduced as an adjunctive option for select patients with resistant hypertension. The guideline also provides expanded recommendations for special populations, including those with chronic kidney disease, diabetes, pregnancy, and neurologic disorders. Enhanced emphasis on home blood pressure monitoring, lifestyle modification, and team-based care highlights the growing importance of patient engagement and coordinated care. The 2025 AHA/ACC Hypertension Guideline marks a pivotal shift toward risk-based, patient-centered hypertension management. It reinforces the need for tailored strategies that bridge clinical practice and population health. Effective implementation will depend on interdisciplinary collaboration and equitable access to preventative and therapeutic resources.
Aorto-Renal Dysplasia in Childhood: The Overlap of Neurofibromatosis Type 1 and Pediatric Renovascular Hypertension.
Singh E, Meyers K, Coleman DM … +1 more , Ganesh SK
Curr Hypertens Rep · 2026 Mar · PMID 41838309 · Full text
PURPOSE OF REVIEW: This narrative review aims to summarize what is currently understood about Neurofibromatosis Type 1 (NF-1) and renovascular hypertension (RVH) in children, including clinical presentation and diagnosis...
PURPOSE OF REVIEW: This narrative review aims to summarize what is currently understood about Neurofibromatosis Type 1 (NF-1) and renovascular hypertension (RVH) in children, including clinical presentation and diagnosis, epidemiology, genetics, and management considerations including advances in treatment modalities. RECENT FINDINGS: Most of what is currently understood about NF-1 and arterial dysplasia leading to RVH relies on the inclusion of patients with NF-1 in single-institution reports. The management of pediatric RVH often requires multi-modal therapies inclusive of anti-hypertensive medications and revascularization for refractory cases, through catheter-based (i.e., endovascular) and open surgical means. There is a need to develop genotype-targeted guidelines for the diagnosis and management of pediatric aorto-renal dysplasia resulting in RVH in patients with NF-1. While our understanding of pediatric RVH and NF-1 has evolved over the past decade, critical research questions have emerged that encompass epidemiology, etiology and genetics. These research questions require immediate attention to establish and optimize standardized diagnostic and treatment guidelines.
Therapeutic Opportunities Targeting the ACE2/Ang-(1-7)/MasR Pathway in Cardiometabolic Disease.
Jayawardena TU, Nagahawatta DP, Grant MB … +2 more , Chappell MC, Oudit GY
Curr Hypertens Rep · 2026 Mar · PMID 41838282 · Publisher ↗
PURPOSE OF REVIEW: This review examines the protective angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas receptor axis of the renin–angiotensin system. We sought to integrate evidence from preclinical and early human...
PURPOSE OF REVIEW: This review examines the protective angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas receptor axis of the renin–angiotensin system. We sought to integrate evidence from preclinical and early human studies on how activation of this pathway influences vascular, cardiac, renal, hepatic and metabolic health, and to identify methodological lessons for developing future therapies. RECENT FINDINGS: Animal models show that augmenting this axis improves endothelial function, limits cardiac remodelling, enhances insulin sensitivity, reduces renal injury and mitigates hepatic steatosis associate with MASH/NAFLD. Early-phase trials of recombinant angiotensin-converting enzyme 2 and angiotensin-(1–7) analogues demonstrate favourable safety profiles and clear pharmacodynamic target engagement but inconsistent immediate clinical effects. Emerging work highlights the value of biomarker ratios, gene and lifestyle based modulation and patient stratification strategies. Activation of the angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas receptor axis offers a promising route to address cardiometabolic disease. Filling gaps in long-term outcomes, receptor-specific mechanisms and precision patient selection could transform this counter-regulatory pathway into a cornerstone of next-generation therapies.
Hypertension Disparities in Immigrant and Refugee Populations: Screening, Treatment Access, and Cultural Barriers.
Ogungbe O, Adebowale O, Turkson-Ocran RN … +12 more , Hinneh T, Metlock FE, Ajibewa TA, Alharthi A, Dugbartey J, Rayani A, Oborevwori E, Teshome B, Koirala B, Baptiste DL, Al-Rousan T, Commodore-Mensah Y
Curr Hypertens Rep · 2026 Mar · PMID 41775931 · Publisher ↗
Hypertension affects over 120 million Americans, yet immigrant and refugee populations face disproportionate barriers to effective hypertension care. With nearly 48 million immigrants and growing refugee populations in t...
Hypertension affects over 120 million Americans, yet immigrant and refugee populations face disproportionate barriers to effective hypertension care. With nearly 48 million immigrants and growing refugee populations in the US, understanding these disparities has become a crucial public health issue. This review synthesizes current evidence on hypertension disparities among immigrant and refugee populations, examining barriers across the hypertension care cascade from screening through control, and discusses promising interventions. Hypertension prevalence varies across immigrant populations. These populations face multiple barriers throughout care: limited screening access, delayed treatment initiation, and poor long-term control. The intersectionality of structural barriers, cultural factors, economic limitations, and healthcare system limitations creates a cumulative cycle of disadvantages. The political threats and "othering" process, discrimination and cultural marginalization, further worsen these challenges, affecting trust, care-seeking behavior, and treatment adherence.Evidence-based interventions show that culturally responsive, community-centered approaches can meaningfully reduce disparities. Community health worker programs achieved remarkable improvements in blood pressure control among immigrant populations. Technology-enhanced interventions, partnerships with faith-based organizations, culturally adapted educational resources, and Clinician cultural humility training often show promising results. However, addressing these disparities requires approaches at the individual, community, healthcare system, and policy levels to be implemented simultaneously. There need to be a sustained commitment to health equity, recognizing that the health of immigrants affects community well-being and the stability of the national and global healthcare system.
Longitudinal Insights Into Pediatric Hypertension, Cardiac Consequences, and Physical Activity.
Corsi DR, Agbaje AO
Curr Hypertens Rep · 2026 Mar · PMID 41772281 · Full text
PURPOSE OF REVIEW: To summarize important novel but controversial discoveries in pediatric hypertension and prevention. This review also aims to provide some answers to previously unexpected findings in randomized clinic...
PURPOSE OF REVIEW: To summarize important novel but controversial discoveries in pediatric hypertension and prevention. This review also aims to provide some answers to previously unexpected findings in randomized clinical trials that failed to lower blood pressure in youth. RECENT FINDINGS: Emerging longitudinal investigations have elucidated the temporal progression of cardiac structural changes, revealing that arterial stiffness precedes the development of hypertension and cardiac remodeling. These temporal insights have important implications for physical activity interventions, as traditional recommendations emphasizing moderate-to-vigorous physical activity to lower blood pressure have demonstrated limited efficacy in randomized controlled trials. Recent evidence suggests that light physical activity provides superior blood pressure-lowering capacity compared to moderate-to-vigorous physical activity due to the confounding effect of muscle mass. Moreover, sedentary behavior may be a causal risk factor for progressive cardiovascular deterioration. Elevated blood pressure and hypertension during childhood and adolescence represent a critical risk factor for premature cardiovascular morbidity and mortality in adulthood. While the association between pediatric hypertension and adverse cardiovascular events is well-established, the temporal sequencing of pathophysiological mechanisms leading from blood pressure elevation to end-organ damage remains unclear. This comprehensive review synthesizes emerging evidence regarding the temporal relationships between pediatric hypertension and cardiac consequences, highlighting temporal trends that could inform evidence-based physical activity interventions for optimizing cardiovascular health trajectories from childhood through young adulthood.
Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges.
Bond RM, Purewal V, Cameron N … +4 more , Tobb K, Adedinsewo D, Isiadinso I, Phillips K
Curr Hypertens Rep · 2026 Feb · PMID 41718913 · Full text
BACKGROUND: Hypertension is a major driver of cardiovascular morbidity and mortality in women, with risk trajectories that evolve across the female life course. From reproductive years through menopause, sex-specific bio...
BACKGROUND: Hypertension is a major driver of cardiovascular morbidity and mortality in women, with risk trajectories that evolve across the female life course. From reproductive years through menopause, sex-specific biological, hormonal, and social factors contribute to unique patterns of blood pressure risk and cardiovascular vulnerability. OBJECTIVE: To provide a life-course review of hypertension in adult women and highlight stage-specific risk factors, clinical considerations, and opportunities for prevention and management. CONTENT: Women experience distinct exposures that influence hypertension risk, including hypertensive disorders of pregnancy, adverse pregnancy outcomes, psychosocial stressors, cardiometabolic changes, and the transition through menopause. This review integrates key recommendations from the 2025 American College of Cardiology/American Heart Association High Blood Pressure Guideline and emphasizes practical, stage-specific approaches to screening, risk stratification, and treatment tailored to women. CONCLUSIONS: A life-stage-specific, sex-informed approach to hypertension is essential to improve early identification, optimize treatment, and reduce long-term cardiovascular risk in women. Addressing persistent evidence gaps and prioritizing implementation of sex-specific care strategies will be critical to advancing equitable cardiovascular outcomes.
Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline.
Reddy TK, Ancha B, Grant JK … +1 more , Ferdinand KC
Curr Hypertens Rep · 2026 Feb · PMID 41714558 · Full text
PURPOSE OF REVIEW: High blood pressure is a leading cause of cardiovascular disease (CVD) morbidity and mortality worldwide, disproportionately affecting racial/ethnic populations in the United States (US). This review s...
PURPOSE OF REVIEW: High blood pressure is a leading cause of cardiovascular disease (CVD) morbidity and mortality worldwide, disproportionately affecting racial/ethnic populations in the United States (US). This review summarizes racial/ethnic inequities in CVD risk, hypertension (HTN), and the social determinants or drivers of health (SDOH), highlighting the 2025 American Heart Association/American College of Cardiology (AHA/ACC) High Blood Pressure Guideline. RECENT FINDINGS: Certain US racial/ethnic populations experience disproportionate HTN burden, with Black adults demonstrating higher rates of resistant, nocturnal and masked HTN, hypertensive disorders of pregnancy, and dementia and cognitive decline. The 2025 AHA/ACC High Blood Pressure Guideline emphasizes the use of a novel race-neutral CVD risk calculator to guide initiation of pharmacotherapy, utilizing patient counseling and shared decision-making, alongside team-based, community-engaged HTN management strategies. The 2025 AHA/ACC High Blood Pressure Guideline advances health equity, integrating the SDOH into improved CVD risk assessment and management recommendations. Effective mitigation of disparities to improve blood pressure and CVD outcomes demands optimizing healthcare access, addressing systemic discrimination, incorporating social context into shared clinical-decision making, and deploying culturally-tailored, community-based interventions.
Insomnia and Hypertension: Importance of Objective Phenotyping and Comorbidity with Sleep Apnea.
Athanasiou N, Vgontzas AN, Fernandez-Mendoza J
Curr Hypertens Rep · 2026 Feb · PMID 41661369 · Full text
PURPOSE OF REVIEW: Provide a synthesis of research from the past five years examining the relationship between insomnia, its phenotypes, and comorbidity with sleep apnea (COMISA), with hypertension. Offer a critical eval...
PURPOSE OF REVIEW: Provide a synthesis of research from the past five years examining the relationship between insomnia, its phenotypes, and comorbidity with sleep apnea (COMISA), with hypertension. Offer a critical evaluation of current evidence and outline future research directions. RECENT FINDINGS: Meta-analytic evidence indicates that the risk of hypertension is higher in patients with insomnia disorder compared to those with insomnia symptoms, with the highest risk observed in the insomnia with objective short sleep duration phenotype. COMISA appears to further amplify this risk, although the evidence is limited to individual studies with no meta-analyses available. There is a clear need for clinical trials to confirm these associations and guide the development of more effective therapeutic strategies. Insomnia should be part of the diagnostic assessment of patients with hypertension. Objective sleep duration can serve as a biomarker, alongside respiratory indices, to guide therapeutic decision-making and optimize patient management.
Pediatric Ambulatory Blood Pressure Patterns and Cardiovascular Risk.
Sill J, Urbina E
Curr Hypertens Rep · 2026 Jan · PMID 41615519 · Full text
PURPOSE OF REVIEW: Pediatric hypertension is associated with antecedent cardiovascular (CV) risk factors and the subsequent development of early subclinical CV disease. Current guidelines recommend the use of ambulatory...
PURPOSE OF REVIEW: Pediatric hypertension is associated with antecedent cardiovascular (CV) risk factors and the subsequent development of early subclinical CV disease. Current guidelines recommend the use of ambulatory blood pressure monitoring (ABPM) to diagnose and classify pediatric hypertension into distinct patterns. In recent years, emerging literature has explored the risk factors linked to these ABPM patterns and the associations of these patterns with target organ damage. This review summarizes studies published in the past five years that examine pediatric ABPM patterns and their relationship to cardiovascular risk. RECENT FINDINGS: ABPM can be used to diagnose hypertension patterns, such as masked hypertension and non-dipping, that can not be identified through office-based measurements alone. This review of recent studies highlights multisystem risk factors that are associated with abnormal ABPM patterns in youth. It also presents growing evidence linking these patterns to target organ damage across pediatric populations with varying cardiovascular risk profiles. Ambulatory blood pressure patterns in pediatric patients can be used to stratify cardiovascular risk in youth, before the onset of cardiovascular events.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe